EHA 2022 Conference Coverage

 

EHA 2022 Conference Coverage
D

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Higher-Risk MDS: 5F9005 Phase 1b Study Results

By EHA 2022 Conference Coverage FEATURING David Sallman
By EHA 2022 Conference Coverage FEATURING David Sallman
255 views
June 22, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
MDS and MPN
30

Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clini…

EHA 2022 Conference Coverage

D. Sallman

24 views
06:24

EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magro…

EHA 2022 Conference Coverage

D. Sallman

399 views
30
EHA 2022 Conference Coverage

[private] Lecture Summary - EHA 2022 on ENHANCE Study: A Randomized …

Feat. D. Sallman
06:24
EHA 2022 Conference Coverage

[private] EHA 2022 on ENHANCE Study: A Randomized Phase 3 Study on M…

Feat. D. Sallman
04:48

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Hi…

EHA 2022 Conference Coverage

D. Sallman

255 views
31

Lecture Summary - EHA 2022 Magrolimab in Combination With Azacitidin…

EHA 2022 Conference Coverage

D. Sallman

14 views
06:43

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated HR…

EHA 2022 Conference Coverage

U. Platzbecker

18 views